On May 29, 2025, researchers from top medical institutions in China published a new study in Med, a leading journal from Cell Press. The study, titled “Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission“, shared promising results from a clinical trial (NCT05859997). It showed that off-the-shelf CD19-targeted CAR-T cell therapy can effectively and safely treat patients with relapsed and hard-to-treat systemic lupus erythematosus (SLE).
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease with no known cure. Current treatment strategies aim to control disease activity, prevent organ damage, and improve long-term prognosis. Standard therapies include glucocorticoids, immunosuppressants, and biologics. However, many patients either do not respond to these treatments or relapse after partial remission, eventually developing life-threatening complications. Improving remission rates, minimizing organ damage, and enhancing quality of life remain pressing global challenges in the treatment of SLE.
B cell dysfunction plays a central role in the pathogenesis of rheumatic autoimmune diseases. Recent clinical studies have begun exploring autologous CD19-targeted CAR-T cell therapies for autoimmune conditions, showing promising initial results. However, autologous CAR-T therapies are often limited by high costs, lengthy preparation times, complex manufacturing, and logistical hurdles, as well as safety concerns.
In earlier work published in Cell in September 2024, researchers demonstrated that allogeneic CD19-targeted CAR-T therapy could be applied to other refractory autoimmune diseases, such as systemic sclerosis and polymyositis, with encouraging efficacy and safety profiles.
Building on this foundation, the current study utilized gene-engineered T cells sourced from healthy donors to produce allogeneic CD19-targeted CAR-T cells, referred to as TyU19. These cells were administered to three patients with severe, relapsed, and treatment-resistant SLE at a major rheumatology center. The patients were monitored over a one-year follow-up period.
The results were striking. The TyU19 cells effectively expanded in vivo and successfully depleted B lymphocytes in all patients. Each patient achieved the Systemic Lupus Erythematosus Responder Index 4 (SRI-4), and proteinuria resolved. Repeat kidney biopsies showed significant pathological improvement, with a marked reduction in CD19 expression in renal tissue. Clinical assessments and laboratory findings further confirmed the favorable safety profile of the treatment.
This study not only offers a promising new therapeutic avenue for patients with refractory lupus but also highlights the broader potential of allogeneic CAR-T cell therapy in the treatment of autoimmune diseases. With continued research and larger clinical trials, this approach may represent a transformative shift in the management of severe autoimmune disorders.
Purpose of this research
The purpose of this research is to build upon earlier findings that demonstrated the feasibility and safety of using allogeneic (off-the-shelf) CD19-targeted CAR-T cells in treating autoimmune diseases. Previously, the research team reported in Cell the world’s first clinical application of allogeneic CAR-T therapy in patients with refractory systemic sclerosis and polymyositis. That study laid the groundwork by confirming that healthy donor-derived CAR-T cells could be used safely and effectively in autoimmune settings.
In the current study, the team extended this therapeutic strategy to treat relapsed and refractory systemic lupus erythematosus (SLE). The use of TyU19, a CD19-targeted allogeneic CAR-T product, led to impressive results: all treated patients achieved complete B cell depletion, met the SLE Responder Index-4 (SRI-4) criteria, and showed significant improvements in kidney function, including the disappearance of proteinuria and notable improvements in renal pathology.
This work suggests that allogeneic CAR-T therapy can induce deep immune reprogramming and even reverse organ damage in patients with severe autoimmune disease. By using T cells from healthy donors, the approach addresses major limitations of autologous CAR-T therapy, such as cost, production time, cell quality, and limited scalability.
Ultimately, this research represents a critical transition from early experimental evidence to potential clinical translation. It offers a promising off-the-shelf CAR-T platform for personalized, precise treatment of rheumatic autoimmune diseases and may mark the beginning of a new era in systemic autoimmune disease therapy.
What is the future outlook for allogeneic (universal) CAR-T cell therapy?
The future of allogeneic (universal) CAR-T cell therapy is highly promising. It overcomes many of the inherent limitations of traditional autologous CAR-T therapy—such as high costs, lengthy manufacturing cycles, and dependency on patient-specific T cells—making it a more accessible and scalable treatment option. More importantly, it holds the potential to become a universal immune-reprogramming platform for treating a wide range of refractory autoimmune diseases.
Looking ahead, future research is expected to focus on several key areas:
- Expansion of Indications: Beyond systemic lupus erythematosus, universal CAR-T therapies may be applied to other challenging autoimmune conditions such as Sjögren’s syndrome, neuromyelitis optica spectrum disorders (NMOSD), and more.
- CAR Design Optimization: Advances may include dual-target constructs or logic-gated CARs to improve specificity, efficacy, and safety.
- Mechanisms of Long-Term Immune Homeostasis: Understanding how these therapies achieve sustained remission and immune balance will be crucial for ensuring durable outcomes.
Equally significant is the strong potential for industrial scalability. With standardized manufacturing and off-the-shelf storage, allogeneic CAR-T cells could become widely accessible and support long-term, sustainable treatment strategies. This represents not only a technological advancement but a fundamental shift in the therapeutic paradigm for autoimmune diseases.
Reference
